Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,501 to 1,520 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Finerenone (BAY94-8862) vs Placebo: Occurence of All-cause Mortality (Full Analysis Set) | 491 of 3,003 522 of 2,998 | -1.1 points -3.0 to 0.8 | 6,001 | NCT04435626 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% |
| Finerenone (BAY94-8862) vs Placebo: Occurrence of Total (First and Recurrent) Heart Failure Events | 479 of 3,003 573 of 2,998 | -3.2 points -5.1 to -1.2 | 6,001 | NCT04435626 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% |
| Finerenone (BAY94-8862) vs Placebo: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events | 624 of 3,003 719 of 2,998 | -3.2 points -5.3 to -1.1 | 6,001 | NCT04435626 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% |
| 10 mg Empagliflozin vs Placebo: deaths from any cause | 422 of 2,997 427 of 2,991 | -0.2 points -2.0 to 1.6 | 5,988 | NCT03057951 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) |
| 10 mg Empagliflozin vs Placebo: serious adverse events | 1,436 of 2,996 1,543 of 2,989 | -3.7 points -6.2 to -1.2 | 5,985 | NCT03057951 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) |
| Fluarix Tetra vs mRNA-1010: Number of Participants With First Episode of RT-PCR Confirmed Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Strain of Influenza Virus | 22 of 2,979 24 of 2,980 | -0.1 points -0.5 to 0.4 | 5,959 | NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults |
| Fluarix Tetra vs mRNA-1010: Number of Participants With First Episode of Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Strain of Influenza Virus | 54 of 2,979 64 of 2,980 | -0.3 points -1.1 to 0.4 | 5,959 | NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults |
| Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Breast Cancer Specific Mortality | 36 of 3,965 19 of 1,992 | -0.0 points -0.6 to 0.4 | 5,957 | NCT02908178 Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ |
| Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Overall Survival | 727 of 3,965 287 of 1,992 | 3.9 points 1.9 to 5.9 | 5,957 | NCT02908178 Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ |
| Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Ipsilateral Invasive Breast Cancer Occurrence | 150 of 3,965 70 of 1,992 | 0.3 points -0.8 to 1.2 | 5,957 | NCT02908178 Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ |
| Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Treated Recurrence | 145 of 3,965 78 of 1,992 | -0.3 points -1.3 to 0.7 | 5,957 | NCT02908178 Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ |
| gD2-AS04 Group vs Pooled Group: Number of Subjects With Serious Adverse Events (SAEs) | 90 of 2,977 100 of 2,978 | -0.3 points -1.2 to 0.6 | 5,955 | NCT00224484 Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old |
| gD2-AS04 Group vs Pooled Group: Number of Subjects With Medically Significant Conditions (MSC) | 69 of 2,977 73 of 2,978 | -0.1 points -0.9 to 0.6 | 5,955 | NCT00224484 Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old |
| gD2-AS04 Group vs Pooled Group: Number of Subjects With New Onset Chronic Diseases (NOCD) | 1 of 2,977 0 of 2,978 | 0.0 points -0.1 to 0.2 | 5,955 | NCT00224484 Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old |
| Hypotension Decision Support vs Usual Care Group: 30-day Mortality | 143 of 1,285 511 of 4,667 | 0.2 points -1.7 to 2.2 | 5,952 | NCT02726620 Decision Support for Intraoperative Low Blood Pressure |
| Intervention Group vs Historical Control Group: deaths from any cause | 86 of 3,206 110 of 2,740 | -1.3 points -2.3 to -0.4 | 5,946 | NCT04294901 Engaging Patients to Promote Deprescribing |
| Appy CDS Intervention vs Control: serious adverse events | 96 of 3,161 109 of 2,779 | -0.9 points -1.8 to 0.0 | 5,940 | NCT02633735 EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care |
| Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke | 384 of 2,954 440 of 2,972 | -1.8 points -3.6 to -0.0 | 5,926 | NCT00153101 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. |
| Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure | 465 of 2,954 504 of 2,972 | -1.2 points -3.1 to 0.7 | 5,926 | NCT00153101 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. |
| Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Non-fatal Myocardial Infarction | 114 of 2,954 145 of 2,972 | -1.0 points -2.1 to 0.0 | 5,926 | NCT00153101 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=76
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04435626-733459c1",
"title": "Finerenone (BAY94-8862) vs Placebo: Occurence of All-cause Mortality (Full Analysis Set)",
"summary": "491 of 3003 against 522 of 2998; risk difference -1.1 points, 95% interval -3.0 to 0.8; NCT04435626, Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%",
"record": "/library/comparisons/NCT04435626-733459c1",
"nct_id": "NCT04435626",
"kind": "outcome",
"participants": 6001,
"risk_difference": {
"value": -0.010612913881759806,
"lower": -0.02957128666987499,
"upper": 0.008348179657930738
},
"group_1": "491 of 3,003",
"group_2": "522 of 2,998",
"difference": "-1.1 points",
"interval": "-3.0 to 0.8",
"trial_title": "Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%"
},
{
"id": "NCT04435626-8ee6dbf7",
"title": "Finerenone (BAY94-8862) vs Placebo: Occurrence of Total (First and Recurrent) Heart Failure Events",
"summary": "479 of 3003 against 573 of 2998; risk difference -3.2 points, 95% interval -5.1 to -1.2; NCT04435626, Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%",
"record": "/library/comparisons/NCT04435626-8ee6dbf7",
"nct_id": "NCT04435626",
"kind": "outcome",
"participants": 6001,
"risk_difference": {
"value": -0.031620258771693055,
"lower": -0.05084363813199356,
"upper": -0.012382903574507841
},
"group_1": "479 of 3,003",
"group_2": "573 of 2,998",
"difference": "-3.2 points",
"interval": "-5.1 to -1.2",
"trial_title": "Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=77",
"request_id": "y7jXp60cEJf_etlA"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant